Accuracy of Sentinel Lymph Node Biopsies Are Vital to Inform Treatment Decisions in Breast Cancer
January 27th 2023The evolving treatment landscape across breast cancer has escalated the need for the accuracy of sentinel lymph node biopsies following treatment with neoadjuvant chemotherapy to correctly inform subsequent treatment decisions for patients.
Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma
January 27th 2023Ciltacabtagene autoleucel demonstrated a significant improvement in progression-free survival in patients with relapsed/lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
January 26th 2023Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.
Zolbetuximab Plus Chemo Extends PFS and OS in CLDN18.2+ Metastatic Gastric Cancer
January 26th 2023Zolbetuximab demonstrated a survival benefit and a tolerable safety profile when combined with mFOLFOX6 vs mFOLFOX6 plus placebo in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, according to primary results from the phase 3 SPOTLIGHT trial.
Phase 1/2 Trial Pauses Enrollment for Evaluation of MGTA-117 in AML/MDS After Patient Death
January 26th 2023Magenta Therapeutics has voluntarily paused enrollment for a phase 1/2 trial evaluating the antibody-drug conjugate MGTA-117 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome following the death of a patient.
European Commission Approves Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer
January 26th 2023Fam-trastuzumab deruxtecan-nxki has received approval in the European Union as a single agent for the treatment of patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent
January 26th 2023The risk for developing hepatocellular carcinoma appears to increase with subsequent generations for Americans of Mexican descent, according to findings from a study of US-born Hispanics/Latinos living in Los Angeles, California.
A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options
January 26th 2023Joyce O’Shaughnessy, MD, highlights key data from the 2022 San Antonio Breast Cancer Symposium, explains how trastuzumab deruxtecan and CDK4/6 inhibitors are altering the treatment landscape, and discusses novel data on steroid receptor expression in triple-negative breast cancer.
KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma
January 25th 2023Maintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant after induction therapy, according to an unplanned interim analysis of the phase 3 ATLAS trial.
Avutometinib Plus Defactinib Generates Responses in Recurrent Low-Grade Serous Ovarian Cancer
January 25th 2023The combination of avutometinib and defactinib elicited responses in patients with recurrent low-grade serious ovarian cancer, according to data from a planned interim analysis of the registration-directed phase 2 RAMP-201 trial.
KEYNOTE-991 Trial of Pembrolizumab Plus Enzalutamide/ADT in mHSPC to Stop for Futility
January 25th 2023Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic hormone-sensitive prostate cancer due to futility.
Pembrolizumab Plus Standard Chemotherapy Improves OS in Biliary Tract Cancer
January 25th 2023Adding the PD-1 inhibitor pembrolizumab to gemcitabine and cisplatin led to a significant improvement in overall survival compared with gemcitabine and cisplatin alone as first-line therapy in patients with advanced or unresectable biliary tract cancer.